Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

被引:32
作者
Yamada, Ryoko [1 ]
Hiramatsu, Naoki [2 ]
Oze, Tsugiko [1 ]
Urabe, Ayako [1 ]
Tahata, Yuki [1 ]
Morishita, Naoki [3 ]
Kodama, Takahiro [1 ]
Hikita, Hayato [1 ]
Sakamori, Ryotaro [1 ]
Yakushijin, Takayuki [4 ]
Yamada, Akira [5 ]
Hagiwara, Hideki [10 ]
Mita, Eiji [6 ]
Oshita, Masahide [7 ]
Itoh, Toshifumi [8 ]
Fukui, Hiroyuki [11 ]
Inui, Yoshiaki [12 ]
Hijioka, Taizo [13 ]
Inada, Masami [14 ]
Katayama, Kazuhiro [9 ]
Tamura, Shinji [3 ]
Inoue, Atsuo [4 ]
Imai, Yasuharu [15 ]
Tatsumi, Tomohide [1 ]
Hamasaki, Toshimitsu [16 ]
Hayashi, Norio [10 ]
Takehara, Tetsuo [1 ]
机构
[1] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Rosai Hosp, Dept Gastroenterol & Hepatol, Sakai, Osaka, Japan
[3] Minoh City Hosp, Dept Gastroenterol & Hepatol, Mino, Japan
[4] Osaka Gen Med Ctr, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Sumitomo Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[6] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Natl Hosp, Osaka, Japan
[7] Osaka Police Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[8] Japan Community Hlth Care Org, Dept Gastroenterol & Hepatol, Osaka Hosp, Osaka, Japan
[9] Osaka Int Canc Inst, Dept Gastroenterol & Hepatol, Osaka, Japan
[10] Kansai Rosai Hosp, Dept Gastroenterol & Hepatol, Amagasaki, Hyogo, Japan
[11] Yao Municipal Hosp, Dept Gastroenterol & Hepatol, Yao, Japan
[12] Hyogo Prefectural Nishinomiya Hosp, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan
[13] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Minami Med Ctr, Kawachi Nagano, Japan
[14] Toyonaka City Hosp, Dept Gastroenterol & Hepatol, Toyonaka, Osaka, Japan
[15] Ikeda Municipal Hosp, Dept Gastroenterol & Hepatol, Ikeda, Osaka, Japan
[16] Natl Cerebral & Cardiovasc Ctr, Dept Gastroenterol & Hepatol, Dept Data Sci, Suita, Osaka, Japan
关键词
chronic hepatitis C; pegylated interferon; risk factor; hepatocellular carcinoma; direct-acting antivirals; EARLY TUMOR RECURRENCE; INTERFERON THERAPY; PLUS RIBAVIRIN; ALPHA; IMPACT;
D O I
10.1111/hepr.13310
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment alpha-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 +/- 26.2 months. Results The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years. Conclusion The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods.
引用
收藏
页码:570 / 578
页数:9
相关论文
共 50 条
  • [31] Effect of Advanced Fibrosis Presence on Adherence to Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C Patients with Sustained Virologic Response
    Sirin, Guktug
    Hulagu, Sadettin
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2020, 26 (01): : 32 - 38
  • [32] Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response
    Ishido, Shun
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Mori, Nami
    Tsuji, Keiji
    Hasebe, Chitomi
    Mashiba, Toshie
    Ochi, Hironori
    Yasui, Yutaka
    Akahane, Takehiro
    Furuta, Koichiro
    Kobashi, Haruhiko
    Fujii, Hideki
    Ishii, Toru
    Marusawa, Hiroyuki
    Kondo, Masahiko
    Kusakabe, Atsunori
    Yoshida, Hideo
    Uchida, Yasushi
    Tada, Toshifumi
    Nakamura, Shinichiro
    Mitsuda, Akari
    Ogawa, Chikara
    Arai, Hirotaka
    Murohisa, Toshimitsu
    Uebayashi, Minoru
    Izumi, Namiki
    JGH OPEN, 2023, 7 (06): : 424 - 430
  • [33] Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails
    Miura, Yukiko
    Shibuya, Akitaka
    Adachi, Shigeru
    Takeuchi, Atsuko
    Tsuchihashi, Takeshi
    Nakazawa, Takahide
    Saigenji, Katsunori
    HEPATOLOGY RESEARCH, 2008, 38 (06) : 546 - 556
  • [34] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon
    Masafumi Ikeda
    Shigetoshi Fujiyama
    Motohiko Tanaka
    Michio Sata
    Tatsuya Ide
    Hiroshi Yatsuhashi
    Hiroshi Watanabe
    Journal of Gastroenterology, 2005, 40 : 148 - 156
  • [35] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon
    Ikeda, M
    Fujiyama, S
    Tanaka, M
    Sata, M
    Ide, T
    Yatsuhashi, H
    Watanabe, H
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (02) : 148 - 156
  • [36] Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Tada, Toshifumi
    Nishimura, Takashi
    Matono, Tomomitsu
    Yoshida, Masahiro
    Yuri, Minako
    Fujiwara, Aoi
    Yuri, Yukihisa
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Ikeda, Naoto
    Enomoto, Hirayuki
    Kumada, Takashi
    Iijima, Hiroko
    HEPATOLOGY RESEARCH, 2021, 51 (08) : 860 - 869
  • [37] Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals
    Tamaki, Nobuharu
    Higuchi, Mayu
    Kurosaki, Masayuki
    Kirino, Sakura
    Osawa, Leona
    Watakabe, Keiya
    Wang, Wan
    Okada, Mao
    Shimizu, Takao
    Takaura, Kenta
    Takada, Hitomi
    Kaneko, Shun
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Enomoto, Nobuyuki
    Izumi, Namiki
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (07) : 893 - 899
  • [38] Comment on: "Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis"
    Ji, Fanpu
    Cai, Zhifang
    Deng, Hong
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (04) : 410 - 410
  • [39] How sustained is sustained viral response in patients with hepatitis C virus infection?
    Sood A.
    Midha V.
    Mehta V.
    Sharma S.
    Mittal R.
    Thara A.
    Sood N.
    Kaur A.
    Indian Journal of Gastroenterology, 2010, 29 (3) : 112 - 115
  • [40] IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
    Ragab, Halla Mohamed
    Abd El Maksoud, Nabila
    Amin, Mona A.
    Halim, Mohab H.
    Abdulla, Nour A.
    Kamel, Abdelkarim
    Moussa, Shorouk M.
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2018, 185 (02) : 484 - 493